2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Evidence from a population-based study on the incidence of human papillomavirus–related cancers indicate a marked decline in cervical carcinoma, potentially due to clear guidance regarding screening measures and HPV vaccination for vulnerable patient groups.
Seventeen years of data from a population-based study presented in a presscast ahead of the 2021 ASCO Annual Meeting have revealed a marked decline in human papillomavirus (HPV)–related cervical carcinoma cases, which may be due to clear guidance on screening measures and HPV vaccination for vulnerable populations.1,2
However, the incidence of other HPV-related cancers without clear screening guidelines are on the rise in both men and women.
“In young women, cervical carcinoma is decreasing consistently with screening, and possibly vaccination, at the population level,” lead author Cheng-I Liao, MD, of Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan, said.
HPV is associated with more than 90% of cervical and anal cancers and 60% to 75% of oropharyngeal, vulvar, vaginal, and penile tumors.3 The purpose of the study was to assess trends in the incidence of HPV-associated cancer using the United States Cancer Statistics Database from 2001 to 2017.
In the 17-year timeframe, there were 657,317 cases of cancer, 393,298 (60%) of which were in women. The most commonly occurring cancer in female patients was cervical carcinoma (52%). In men (n = 264,019), the most common malignancy was oropharyngeal squamous cell carcinoma (SCC; 80%), which represents a 5-fold higher incidence compared with women.
Over the study period, cervical cancer incidence decreased by 1.03% per year (P <.05), but this rate was significantly higher in patients aged 20 to 24 years who saw a much greater decrease in disease incidence, at 4.63% per years. Similar effects were seen in women over the age of 65, who saw a greater than 2% incidence decline over the study period (P <.05). The investigators said this is likely due to the effects of HPV vaccination and screening.
However, other HPV-related cancers without standardized screening guidelines saw increases over the study period, with a 2.71% incidence rise per year in men and a 0.77% increase in women. Other HPV-associated cancers included anal and rectal SCC, oropharyngeal SCC, penile cancer, vulvar SCC, and vaginal SCC.
In women over the age of 50, the annual percentage change in the incidence of anal and rectal SCC was 3.55% (P <.001). When compared with the 1.53% decline in the incidence of cervical cancer in the same patient population (P <.001), trends suggest that HPV-related anal and rectal SCC will surpass its incidence in the coming decade, and likely in the next 5 years.
“The decrease in cervical cancer is welcome news and may reflect intensive efforts to screen and vaccinate patients at risk,” ASCO President Lori J. Pierce, MD, FASTRO, FASCO, said in a press release. “Clearly, this study shows that we still have a great deal of work to do in order to reverse the increasing incidence rates of other HPV-related cancers.”
The investigators plan to gather information from other databases about the rate of HPV testing and vaccination. Additional research will be necessary to tackle a lack of disease screening and vaccination recommendations for HPV-associated cancers other than cervical.